Publication Name	World Journal of Pharmacology
Manuscript ID	66320
Country	Iran

Received	2021-03-25 09:04
Peer-Review Started	2021-03-25 09:07
To Make the First Decision
Return for Revision	2021-07-27 06:30
Revised	2021-08-11 21:33
Second Decision	2022-01-11 03:44
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2022-01-11 19:54
Articles in Press	2022-01-11 19:54
Publication Fee Transferred
Edit the Manuscript by Language Editor	2022-01-07 17:18
Typeset the Manuscript	2022-01-19 16:23
Publish the Manuscript Online	2022-01-25 07:27

ISSN	2220-3192 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Copyright	© The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Pharmacology & Pharmacy
Manuscript Type	Editorial
Article Title	Mammalian target of rapamycin; novel insight for management of inflammatory bowel diseases
Manuscript Source	Invited Manuscript
All Author List	Naser-Aldin Lashgari, Nazanin Momeni Roudsari, Saeideh Momtaz and Amir Hossein Abdolghaffari
Funding Agency and Grant Number
Corresponding Author	Amir Hossein Abdolghaffari, PhD, Assistant Professor, Department of Toxicology and Pharmacology, Faculty of Pharmacy, Tehran Medical Sciences, Islamic Azad University, No. 99, Yakhchal, Gholhak, Shariati St., Tehran 1941933111, Iran. amirhosein172@hotmail.com
Key Words	Inflammatory bowel diseases; Inflammation; Mammalian target of rapamycin; Mammalian target of rapamycin inhibitors
Core Tip	Inflammation is the main participant in inflammatory bowel diseases (IBD) pathogenesis and development. Since the mammalian target of rapamycin (mTOR) pathways are suggested to be involved in IBD progression, inhibition of the mTOR signaling may lead to a novel treatment modality for patients with IBD. Several biologics, synthetic and natural compounds were introduced as mTOR inhibitors, which may be favorable, preferably in clinical state, to either control or eradicate the intestinal inflammatory conditions such as IBD.
Publish Date	2022-01-25 07:27
Citation	Lashgari NA, Roudsari NM, Momtaz S, Abdolghaffari AH. Mammalian target of rapamycin; novel insight for management of inflammatory bowel diseases. World J Pharmacol 2022; 11(1): 1-5
URL	https://www.wjgnet.com/2220-3192/full/v11/i1/1.htm
DOI	https://dx.doi.org/10.5497/wjp.v11.i1.1

Full Article (PDF)	WJP-11-1.pdf
Full Article (Word)	WJP-11-1.docx
Manuscript File	66320_Auto_Edited-JRF-Kerr C.docx
Answering Reviewers	66320-Answering reviewers.pdf
Audio Core Tip	66320-Audio core tip.m4a
Conflict-of-Interest Disclosure Form	66320-Conflict-of-interest statement.pdf
Copyright License Agreement	66320-Copyright license agreement.pdf
Non-Native Speakers of English Editing Certificate	66320-Language certificate.pdf
Peer-review Report	66320-Peer-review(s).pdf
Scientific Misconduct Check	66320-Bing-Fan JR-2.png
Scientific Editor Work List	66320-Scientific editor work list.pdf